What is the upside for Vericel's stock?
On average, they anticipate Vericel's stock price to reach $23.23 in the next twelve months. This suggests a possible upside of 23.1% from the stock's current price. View Analyst Price Targets for Vericel.
What are the target prices for Vericel's shares?
7 brokers have issued 1-year target prices for Vericel's shares. Their forecasts range from $31.00 to $65.00. On average, they anticipate Vericel's share price to reach $50.00 in the next year. This suggests that the stock has a possible downside of 2.0%.
Where can I buy shares of vcel?
Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
How has Vericel's stock price been impacted by covid-19 (coronavirus)?
Vericel had a net margin of 5.78% and a trailing twelve-month return on equity of 6.49%. The firm's revenue was up 97.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.18) EPS. View Vericel's earnings history. How has Vericel's stock price been impacted by COVID-19 (Coronavirus)?
Should I buy or sell Vericel stock right now?
3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 2...
What is Vericel's stock price forecast for 2022?
3 Wall Street analysts have issued twelve-month target prices for Vericel's stock. Their forecasts range from $45.00 to $52.00. On average, they an...
How has Vericel's stock price performed in 2022?
Vericel's stock was trading at $39.30 at the start of the year. Since then, VCEL shares have decreased by 37.0% and is now trading at $24.75. View...
When is Vericel's next earnings date?
Vericel is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for Vericel .
How were Vericel's earnings last quarter?
Vericel Co. (NASDAQ:VCEL) announced its quarterly earnings data on Wednesday, May, 4th. The biotechnology company reported ($0.15) EPS for the quar...
What guidance has Vericel issued on next quarter's earnings?
Vericel issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period....
Who are Vericel's key executives?
Vericel's management team includes the following people: Mr. Dominick C. Colangelo Esq. , CEO, Pres & Director (Age 58, Pay $1.36M) Mr. Joseph A...
What is Nick Colangelo's approval rating as Vericel's CEO?
6 employees have rated Vericel CEO Nick Colangelo on Glassdoor.com . Nick Colangelo has an approval rating of 49% among Vericel's employees. This...
Who are some of Vericel's key competitors?
Some companies that are related to Vericel include Ablynx (ABLYF) , Abcam (ABCM) , Novavax (NVAX) , Vir Biotechnology (VIR) , Denali Therapeut...
Who owns Vericel stock?
When is Vericel earnings call?
Vericel's stock is owned by a number of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.07%) and Oregon Public Employees Retirement Fund (0.04%).
When is Vericel 2021?
How can I listen to Vericel's earnings call? Vericel will be holding an earnings conference call on Wednesday, August 4th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "5824035".
Is Tuesday a good day for Vericel?
Vericel to Present at the Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021. CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, ...
Signals & Forecast
Tuesday was not a good day to be a Vericel (NASDAQ: VCEL) investor. In what must have been a painful admission, Vericel announced Tuesday morning that the biotech's development partner MediWound received what amounts to a rejection letter from the FDA.
Support, Risk & Stop-loss
A buy signal was issued from a pivot bottom point on Thursday, January 27, 2022, and so far it has risen 10.13%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD).
Is Vericel Corporation stock A Buy?
Vericel Corporation finds support from accumulated volume at $33.91 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are neutral selling more shares than they are buying in Vericel Corporation
Vericel Corporation holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
About Vericel Corporation
In the last 100 trades there were 254.7 thousand shares bought and 286.85 thousand shares sold. The last trade was done 10 days ago by Halpin Michael who sold 3.5 thousand shares. In general the insiders are selling more stocks than they buy. There can be a variety of reasons for this, but in general it can be considered as a negative signal.
Golden Star Signal
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
